The Transplant Sessions: ASH 2020 highlights

The management of post-transplantation relapse and immune attack is an ongoing battle in patients undergoing bone marrow transplants. The efficacy and safety of therapy options for graft-versus-host disease is part of a larger conversation aimed at improving the outcomes of patients after transplantation. Ongoing research has seen interesting directions with the advent of antigen escape targeted therapies and combination of gamma-secretase inhibitors. Cellular therapy such as CAR-T is on the rise in this field with a collective aim for durability in response.

The 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition (ASH 2020) was held virtually this year due to the COVID pandemic – but this did not affect the quality and quantity of data presented, where research was presented from around the globe for improved patient care.

In this roundtable discussion, leading experts Bruce Levine, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA and Christian Chabannon MD, PhD, Paoli-Calmettes Institute, Marseille, France, present the latest in the management of graft failure, graft-versus-host disease, post-transplant relapse and cellular therapies from the ASH 2020 virtual Annual Meeting and share how the new research and clinical updates can induce durability in patient management strategies in clinical practice.